ArticleJournal of diabetes science and technology2016
First Clinical Experience with Retrospective Flash Glucose Monitoring (FGM) Analysis in South Africa: Characterizing Glycemic Control with Ambulatory Glucose Profile.
Article in Journal of diabetes science and technology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05944718 (Three-arm Pragmatic Randomized Study on the Effectiveness, Feasibility, Acceptability, and Cost of the Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in South Africa), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Three-arm Pragmatic Randomized Study on the Effectiveness, Feasibility, Acceptability, and Cost of the Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in South Africa
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical Recommendations for the Use of the Ambulatory Glucose Profile in Diabetes Care.Journal of diabetes science and technology · 2020Guideline
- Trial
- Trial
- Effect of Different Nutritional Supplements on Glucose Response of Complete Meals in Two Crossover Studies.Nutrients · 2022Trial
- Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial.Diabetes & vascular disease research · 2019Trial
- Continuous Glucose Monitoring Captures Glycemic Variability After Roux-en-Y Gastric Bypass in Patients with and Without Type 2 Diabetes Mellitus: A Prospective Cohort Study.Obesity surgery · 2024Article
- Frequent scanning using flash glucose monitoring contributes to better glycemic control in children and adolescents with type 1 diabetes.Journal of diabetes investigation · 2022Article
- A comparison of FreeStyle Libre 2 to self-monitoring of blood glucose in children with type 1 diabetes and sub-optimal glycaemic control: a 12-week randomised controlled trial protocol.Journal of diabetes and metabolic disorders · 2021Article
- Association of sleep quality with glycemic variability assessed by flash glucose monitoring in patients with type 2 diabetes.Diabetology & metabolic syndrome · 2021Article
- Point-of-care HbABMJ open · 2021Article
- Using Continuous Glucose Monitoring in Clinical Practice.Clinical diabetes : a publication of the American Diabetes Association · 2020Article
- Comparison of oral glucose tolerance test and ambulatory glycaemic profiles in pregnant women in Uganda with gestational diabetes using the FreeStyle Libre flash glucose monitoring system.BMC pregnancy and childbirth · 2020Observational
- Article
- Flash Continuous Glucose Monitoring: Implications for Use of Continuous Data in Daily Diabetes Management.Diabetes spectrum : a publication of the American Diabetes Association · 2019Article
- The Potential Impact of the FreeStyle Libre Flash Glucose Monitoring System on Mental Well-Being and Treatment Satisfaction in Patients with Type 1 Diabetes: A Prospective Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Article
- Are the recorded data of flash glucose monitoring systems influenced by radiological examinations?Radiological physics and technology · 2019Article
- Using Flash Continuous Glucose Monitoring in Primary Practice.Clinical diabetes : a publication of the American Diabetes Association · 2019Article
- Flash Glucose Monitoring: A Review of the Literature with a Special Focus on Type 1 Diabetes.Nutrients · 2018Review
- The new FreeStyle libre flash glucose monitoring system improves the glycaemic control in a cohort of people with type 1 diabetes followed in real-life conditions over a period of one year.Endocrinology, diabetes & metabolism · 2018Article
- Our First 825 T2DM Patients on 14-Day Factory-Calibrated Glucose Monitoring System: Clinical Utility and Challenges.Journal of diabetes science and technology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2014, an innovative blinded continuous glucose monitoring system was introduced with automated ambulatory glucose profile (AGP) reporting. The clinical use and interpretation of this new technology has not previously been described. Therefore we wanted to understand its use in characterizing key factors related to glycemic control: glucose exposure, variability, and stability, and risk of hypoglycemia in clinical practice.
methodsClinicians representing affiliated diabetes centers throughout South Africa were trained and subsequently were given flash glucose monitoring readers and 2-week glucose sensors to use at their discretion. After patient use, sensor data were collected and uploaded for AGP reporting.
resultsComplete data (sensor AGP with corresponding clinical information) were obtained for 50 patients with type 1 (70%) and type 2 diabetes (30%), irrespective of therapy. Aggregated analysis of AGP data comparing patients with type 1 versus type 2 diabetes, revealed that despite similar HbA1c values between both groups (8.4 ± 2 vs 8.6 ± 1.7%, respectively), those with type 2 diabetes had lower mean glucose levels (9.2 ± 3 vs 10.3 mmol/l [166 ± 54 vs 185 mg/dl]) and lower indices of glucose variability (3.0 ± 1.5 vs 5.0 ± 1.9 mmol/l [54 ± 27 vs 90 ± 34.2 mg/dl]). This highlights key areas for future focus.
conclusionsUsing AGP, the characteristics of glucose exposure, variability, stability, and hypoglycemia risk and occurrence were obtained within a short time and with minimal provider and patient input. In a survey at the time of the follow-up visit, clinicians indicated that aggregated AGP data analysis provided important new clinical information and insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.